搜尋關鍵字
搜尋關鍵字
Under-treatment. Over-treatment. Neither is desirable, and precise diagnosis is critical to determine the best treatment pathway, optimizing tumor control while sparing healthy tissue.
See what various healthcare teams are doing right now to address the diagnostic uncertainty that can complicate cancer treatment. This article will give you an overview of the advances for earlier, more accurate diagnosis and staging in prostate cancer and shorter, more effective treatment pathways in lung cancer.
Challenge
Accuracy in diagnostics and treatment is a challenge in many types of cancer, including prostate and lung cancer.
Solution
Philips integrated solutions are guiding early, accurate cancer diagnosis and treatment.
Results
With prostate cancer, 30% improvement in detection of aggressive cancer1
In lung cancer, more than 91% sensitivity for malignancy and 84% diagnostic yield for small lung nodules2
The current approach to prostate cancer diagnosis is characterized by a considerable degree of diagnostic uncertainty. This uncertainty has contributed to both overtreatment and undertreatment and has left the medical community uncertain of the most effective method for diagnosing prostate cancer." 3
Fortunately, precision targeting and enhanced image-guided biopsy for prostate cancer are allowing for greater diagnostic certainty than previous approaches. It starts with connecting radiology and urology. Current methods of prostate cancer screening are somewhat unreliable and can lead to many uncertainties. Prostate biopsy, the most common method of detection,3 is a challenge because of difficulties in visualizing not only the entirety of the prostate, but also the location of the biopsy needle. Transrectal ultrasound-guided prostate biopsy (TRUS), the current biopsy standard, commonly suffers from poor image resolution, and the biopsy needle often passes through tumor-free areas of the prostate - potentially missing the tumor entirely.
Fusing pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time provides excellent delineation of the prostate and suspicious lesions, as well as clear visualization of the biopsy needle path. Combining tracking and navigation with real-time imaging brings precision targeting for the biopsy samples.
We're saving 40% of biopsies. Not only is that a saving in monetary terms, it's also a saving of patients’ side effects. It's a saving of further investigations downstream." *
Christof Kastner, PhD, FRCS (Urol), FEBU
Consultant Urologist & Prostate Cancer Lead, Cambridge University Hospitals
This is a very exciting time in the world of interventional pulmonology and advanced bronchoscopy. There’s been an explosion in the research and development of newer technologies."
Dr. Michael Pritchett
Pulmonologist, Pinehurst, NC
Challenge
Accuracy in diagnostics and treatment is a challenge in many types of cancer, including prostate and lung cancer.
Solution
Philips integrated solutions are guiding early, accurate cancer diagnosis and treatment.
Results
With prostate cancer, 30% improvement in detection of aggressive cancer1
In lung cancer, more than 91% sensitivity for malignancy and 84% diagnostic yield for small lung nodules2
1. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397.
2. Pritchett M, et al. Cone beam CT-guided endobronchial biopsy assisted by augmented fluoroscopy. Chest. 2017;152.4: A 8 87.
3. Ahdoot M, Wilbur AR, Reese, SE, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917-928
doi: 10.1056/NEJMoa1910038
4. International Agency for Research on Cancer, World Health Organization. Press Release N°263. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 12 September 2018.
5. Survival after community diagnosis of early-stage non-small cell lung cancer. The Am J Med. 2014;127 (5):443-449.
6. International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476
7. Abi-Jaoudeh, Nadine, et al. Prospective randomized trial for image-guided biopsy using cone-beam CT navigation compared with conventional CT. J Vasc Interv Radiol. 2016 27.9 1342-1349.
8. Yan, Gao-Wu, et al. A systematic review and meta-analysis of C-Arm Cone-Beam CT-guided percutaneous transthoracic needle biopsy of lung nodules. Pol J Radiol. 2017;82:152.
9. Zhao, Ze-Rui, Rainbow WH Lau, and Calvin SH Ng. Hybrid theatre and alternative localization techniques in conventional and single-port video-assisted thoracoscopic surgery. J Thorac D. 2016; 8.Suppl 3: S319.
10. Results obtained during user tests performed in the period of November 2015 - February 2016. The tests were designed and supervised by Use-Lab GmbH, an independent and objective usability testing engineering consultancy and user interface design company. The tests involved 31 US-based clinicians (16 physicians and 15 technicians) and 30 European-based clinicians (15 physicians and 15 technologists), who performed procedures using Azurion in a simulated interventional lab environment.
